跳至主要内容
临床试验/EUCTR2011-005526-22-AT
EUCTR2011-005526-22-AT进行中(未招募)不适用

Tissue concentration of cefazolin and linezolid in sternal spongiosa in elective coronary artery bypass grafting: an in-vivo microdialysis study - Bone antibiotic concentration in CABG

Medizinische Universität Wien0 个研究点开始时间: 2012年3月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Written informed consent
  • -Planned coronary artery bypass grafting
  • -Planned used of cardiopulmonary bypass
  • -Age = 18 and = 90 years
  • -No pre-existing liver or kidney disease
  • -Left ventricular ejection fraction > 40%
  • -No pre-existing osteoporosis requiring therapy
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • -Preoperative antibiotic treatment
  • -Preoperative signs of infection
  • -Inability to give informed consent or missing informed consent
  • -Know allergy to cephalosporins, penicillin or Linezolid
  • -Re-operation
  • -Additional planned valve surgery
  • -Preoperative renal replacement therapy
  • -BMI > 40
  • -Long standing diabetes mellitus (> 7 years)
  • -Preoperative osteoporosis requiring therapy
  • -Age <18 or >90
  • -Chronic severe liver or renal insufficiency
  • -Childbearing potential
  • -Drug or alcohol abuses
  • -Psychiatric disease
  • -Treatment with MAO – inhibiting or serotonergic medication

研究者

相似试验